Bortezomib — active pharmaceutical ingredient (API) manufactured to pharmacopoeial specification. Purity ≥99.0%. CAS Registry Number: 179324-69-7. Supplied in bulk quantities from $180000.00/g entry for laboratory research, analytical method development, and reference-standard applications.
We maintain regulatory dossiers in the following jurisdictions for Bortezomib-relevant molecules. Letter of Authorization (LoA) and CEP / DMF / ASMF references are issued at no charge to qualified buyers.
Bortezomib is supplied as a pharmaceutical-grade human apis for use by regulated pharmaceutical manufacturers, contract development and manufacturing organisations (CDMOs), and research institutions. Buyers using Bortezomib typically reference it under CAS Registry Number 179324-69-7.
Our Bortezomib is manufactured under WHO-GMP and ISO 9001:2015 conditions in Pune, India. Per-batch Certificate of Analysis (CoA) is released against USP / Ph. Eur. / IP / JP specifications depending on destination market. We hold US FDA Drug Master File and EDQM Certificate of Suitability dossiers for the molecules where regulatory recognition is required; Letter of Authorization (LoA) is issued at no charge to qualified buyers.
Quote requests for Bortezomib are turned around within 24 business hours (IST, Pune). Bulk APIs typically ship within 7-10 business days of confirmed PO; air freight to North America and Europe runs 4-5 days door-to-door. Sample agreements are signed before shipping QC-grade material to your formulation laboratory.
We export Bortezomib to 50+ countries including the United States, Canada, Mexico, Brazil, the European Union, the United Kingdom, Japan, Australia, South Korea, the GCC and across South-East Asia. All regulatory documents (DMF / CEP / LoA) and shipping incoterms (EXW, FCA, CIP, DAP, DDP) are negotiated per buyer.
Browse our Human APIs catalogue or the full 560+ product directory. Reference documents: certifications portfolio · quality system · FDA DMF buyer guide · EU CEP supplier guide.